Department of Medicine, San Francisco General Hospital, University of California-San Francisco, 1001 Potrero Avenue, San Francisco, CA 94143, USA.
Malar J. 2013 Jul 19;12:252. doi: 10.1186/1475-2875-12-252.
Most African countries have adopted artemisinin-based combination therapy (ACT) as the first-line treatment for uncomplicated malaria. The World Health Organization now recommends limiting anti-malarial treatment to those with a positive malaria test result. Limited data exist on how these policies have affected ACT prescription practices.
Data were collected from all outpatients presenting to six public health facilities in Uganda as part of a sentinel site malaria surveillance programme. Training in case management, encouragement of laboratory-based diagnosis of malaria, and regular feedback were provided. Data for this report include patients with laboratory confirmed malaria who were prescribed anti-malarial therapy over a two-year period. Patient visits were analysed in two groups: those considered ACT candidates (defined as uncomplicated malaria with no referral for admission in patients ≥ 4 months of age and ≥ 5 kg in weight) and those who may not have been ACT candidates. Associations between variables of interest and failure to prescribe ACT to patients who were ACT candidates were estimated using multivariable logistic regression.
A total of 51,355 patient visits were included in the analysis and 46,265 (90.1%) were classified as ACT candidates. In the ACT candidate group, 94.5% were correctly prescribed ACT. Artemether-lumefantrine made up 97.3% of ACT prescribed. There were significant differences across the sites in the proportion of patients for whom there was a failure to prescribe ACT, ranging from 3.0-9.3%. Young children and woman of childbearing age had higher odds of failure to receive an ACT prescription. Among patients who may not have been ACT candidates, the proportion prescribed quinine versus ACT differed based on if the patient had severe malaria or was referred for admission (93.4% vs 6.5%) or was below age or weight cutoffs for ACT (41.4% vs 57.2%).
High rates of compliance with recommended ACT use can be achieved in resource-limited settings. The unique health facility-based malaria surveillance system operating at these clinical sites may provide a framework for improving appropriate ACT use at other sites in sub-Saharan Africa.
大多数非洲国家已将青蒿素为基础的联合疗法(ACT)作为治疗轻症疟疾的一线疗法。世界卫生组织现在建议将抗疟治疗限制在疟疾检测结果阳性的患者。关于这些政策如何影响 ACT 处方实践,目前的数据有限。
数据来自乌干达六个公共卫生机构的所有门诊患者,作为哨点疟疾监测计划的一部分。提供了病例管理培训、鼓励基于实验室的疟疾诊断以及定期反馈。本报告的数据包括在两年期间接受抗疟治疗的实验室确诊疟疾患者。对患者就诊情况进行了两组分析:被认为是 ACT 候选者(定义为无转诊住院指征且年龄≥4 个月且体重≥5 公斤的轻症疟疾患者)和可能不是 ACT 候选者。使用多变量逻辑回归估计了感兴趣变量与未向 ACT 候选者患者开具 ACT 之间的关联。
共分析了 51355 例患者就诊情况,其中 46265 例(90.1%)被归类为 ACT 候选者。在 ACT 候选者组中,94.5%的患者正确开具了 ACT。ACT 处方中 97.3%为青蒿琥酯-阿莫地喹。各监测点之间未能开具 ACT 的患者比例存在显著差异,范围为 3.0-9.3%。幼儿和育龄妇女接受 ACT 处方的可能性较低。在可能不是 ACT 候选者的患者中,根据患者是否患有重症疟疾或是否转诊住院(93.4%比 6.5%)或是否低于 ACT 的年龄或体重标准(41.4%比 57.2%),开具奎宁与 ACT 的比例不同。
在资源有限的环境中,可以实现遵守推荐使用 ACT 的高比率。在这些临床场所运行的独特基于卫生机构的疟疾监测系统可能为改善撒哈拉以南非洲其他地区适当使用 ACT 提供框架。